Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SUPN 
Supernus Pharmaceuticals Inc (SUPN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: SUPN (4-star) is a STRONG-BUY. BUY since 64 days. Simulated Profits (46.84%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $54.2
1 Year Target Price $54.2
| 2 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.96% | Avg. Invested days 53 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.76B USD | Price to earnings Ratio 42.07 | 1Y Target Price 54.2 |
Price to earnings Ratio 42.07 | 1Y Target Price 54.2 | ||
Volume (30-day avg) 5 | Beta 0.78 | 52 Weeks Range 29.16 - 51.78 | Updated Date 10/14/2025 |
52 Weeks Range 29.16 - 51.78 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.7% | Operating Margin (TTM) 6.73% |
Management Effectiveness
Return on Assets (TTM) 2.39% | Return on Equity (TTM) 6.38% |
Valuation
Trailing PE 42.07 | Forward PE 20.16 | Enterprise Value 2198443300 | Price to Sales(TTM) 4.15 |
Enterprise Value 2198443300 | Price to Sales(TTM) 4.15 | ||
Enterprise Value to Revenue 3.31 | Enterprise Value to EBITDA 12.62 | Shares Outstanding 56073088 | Shares Floating 48802091 |
Shares Outstanding 56073088 | Shares Floating 48802091 | ||
Percent Insiders 4.36 | Percent Institutions 109.46 |
Upturn AI SWOT
Supernus Pharmaceuticals Inc
Company Overview
History and Background
Supernus Pharmaceuticals, Inc. was founded in 2005. It is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company has grown through organic development and strategic acquisitions.
Core Business Areas
- Neurology: Focuses on treatments for neurological disorders such as epilepsy, ADHD, and Parkinson's disease.
- Psychiatry: Develops treatments for psychiatric disorders, including depression.
Leadership and Structure
The leadership team is headed by CEO Jack Khattar. The organizational structure includes departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Oxtellar XR: An extended-release formulation of oxcarbazepine used for the treatment of epilepsy. Competitors include generic oxcarbazepine and other antiepileptic drugs such as lamotrigine (LTG).
- Trokendi XR: An extended-release formulation of topiramate used for the treatment of epilepsy and migraine prevention. Competitors include generic topiramate, Qsymia, and Topamax.
- Aptiom: An antiepileptic drug. Competitors include Keppra and Vimpat.
- Qelbree: Non-stimulant medication for the treatment of ADHD. Competitors include stimulants like Adderall (SHPG) and non-stimulants like Strattera (LLY).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Companies face challenges related to drug development, regulatory approvals, and patent protection. The CNS market is characterized by a high unmet need and growing awareness of mental health issues.
Positioning
Supernus focuses on developing differentiated products with improved efficacy and safety profiles. Their strengths lie in extended-release formulations and novel therapeutics for CNS disorders.
Total Addressable Market (TAM)
The global CNS therapeutics market is estimated to be several billion dollars. Supernus is positioned to capture a significant portion of this TAM through its existing product portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Strong portfolio of CNS products
- Expertise in extended-release formulations
- Established commercial infrastructure
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Exposure to generic competition
- High R&D costs
- Dependence on insurance reimbursement for drug sales
Opportunities
- Expansion of product pipeline through acquisitions or licensing
- Geographic expansion into new markets
- Development of novel therapeutics for unmet needs in CNS disorders
- Strategic partnerships with other pharmaceutical companies
Threats
- Generic erosion of key products
- Regulatory challenges and delays in drug approvals
- Increased competition from other pharmaceutical companies
- Changes in healthcare policies and reimbursement
Competitors and Market Share
Key Competitors
- TEVA
- LLY
- VTRS
- SHPG
Competitive Landscape
Supernus competes with major pharmaceutical companies and generic drug manufacturers. Its advantages include differentiated products and expertise in CNS disorders. Its disadvantages include a limited product portfolio and reliance on key products.
Major Acquisitions
Bravel Bio
- Year: 2024
- Acquisition Price (USD millions): 80
- Strategic Rationale: Adds novel compound SPN-830, intended to treat tardive dyskinesia.
Growth Trajectory and Initiatives
Historical Growth: Supernus has experienced revenue growth driven by its key products. Future growth will depend on successful product launches and pipeline development.
Future Projections: Analysts project continued revenue growth for Supernus, driven by the expansion of its existing product portfolio and the launch of new products.
Recent Initiatives: Recent initiatives include the acquisition of new products and companies to expand their pipeline and commercial presence.
Summary
Supernus is a growing biopharmaceutical company focused on CNS disorders. Its strengths include a strong product portfolio and expertise in extended-release formulations. Its weaknesses include reliance on a limited number of products and exposure to generic competition. Key opportunities lie in expanding the product pipeline and geographic reach. Supernus needs to manage generic competition and regulatory challenges effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Supernus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2012-05-01 | Founder, President, CEO, Secretary & Director Mr. Jack A. Khattar M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 674 | Website https://www.supernus.com |
Full time employees 674 | Website https://www.supernus.com | ||
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.